AI CAPITAL INTELLIGENCE
柏垠生物 funding history
1 recorded financing disclosures for 柏垠生物. Dates, rounds, currencies and original sources follow the individual records. This is not a complete company funding history.
Latest recorded funding, at a glance
The latest disclosure recorded for 柏垠生物 is dated 2026-10-22: Multiple rounds, Lower bound: CNY 200,000,000. Named investors: 沃博联广药基金, 欧莱雅BOLD基金, 富华资本, 基石资本, 星博生辉, 君科丹木, 广新基金. This is the latest record in our coverage, not a claim about all company financing.
View funding details · Original source 1 · Original source 2 · Original source 3 · Original source 4
Funding disclosures
| Disclosure date | Round | Disclosed amount | Named investors | Evidence |
|---|---|---|---|---|
| Multiple rounds | Lower bound: CNY 200,000,000 | 沃博联广药基金, 欧莱雅BOLD基金, 富华资本, 基石资本, 星博生辉, 君科丹木, 广新基金 | Record · Source 1 · Source 2 · Source 3 · Source 4 |
Recorded financing disclosures
- 柏垠生物2026-10-22 · Multiple rounds · Lower bound: CNY 200,000,000
Disclosed investors across recorded rounds
Publicly disclosed founding team
- 钟超 · 创始人
Source bibliography
- 创新AI原生生物材料企业柏垠生物完成超2亿元A轮系列融资
news.pedaily.cn · Original publication date not recorded
- 【首发】获多家世界500强产业资本支持，柏垠生物完成超2亿元A轮系列融资医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
bydrug.pharmcube.com · Original publication date not recorded
- 柏垠生物完成超2亿元A轮系列融资
tech.sina.cn · Original publication date not recorded
- 2026Q2 中国院内外药品市场销售分析报告_医药魔方
bydrug.pharmcube.com · Original publication date not recorded
Citation and coverage
Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market.
Wavesight AI｜柏垠生物 funding history。The latest disclosure recorded for 柏垠生物 is dated 2026-10-22: Multiple rounds, Lower bound: CNY 200,000,000. Named investors: 沃博联广药基金, 欧莱雅BOLD基金, 富华资本, 基石资本, 星博生辉, 君科丹木, 广新基金. This is the latest record in our coverage, not a claim about all company financing. Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market. https://www.zkdlj.vip/en/companies/profile/EN-48901d83aaf2d3df/#conclusion-overview
Link to conclusion